


Taiwanese startup JelloX Biotech opens new horizons for AI-powered 3D pathology

03 April 2023 | News

Two new research breakthroughs involving the company and its technologies make inroads into new possibilities for medicine



JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, has announced involvement with two new research breakthroughs that demonstrate expanded potential for its specialised technology combining 3D imaging and artificial intelligence (AI).

3D imaging and digital pathology are currently viewed by the healthcare industry as prohibitively expensive due to the need for costly graphics tools, but JelloX's solution for this is MetaLite — a cost-effective software platform that leverages AI to analyse 3D-rendered thick tissue images rapidly, saving pathologists hours while improving diagnostic precision.

Published in February 2023, Dr Lin-Shien Fu, Director of the Pediatric Nephrology and Immunology Department at Taiwan's Taichung Veterans General Hospital, released a *paper* that showed that 3D pathology can facilitate pathological analysis of kidney inflammation from lupus, also known as lupus nephritis.

In its forte of cancer pathology, JelloX experts published a recent research paper to demonstrate that the AI deep learning techniques powering JelloX's technology, and AI more broadly, can effectively analyse a combination of image types and distinguish between them.

To showcase its leadership in 3D pathology and AI, JelloX will attend the upcoming BIO 2023 conference on June 5-8 in Boston, where it will highlight its recent research breakthroughs in addition to its AI-powered MetaLite software platform.